Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.47 +11.0%	$1.78	$1.03 ▼ $2.64	$491.84M	1.48	1.70 million shs	375,224 shs
CMPS COMPASS Pathways	$4.93 +10.0%	$3.97	$2.49 ▼ $8.54	$460.78M	2.25	906,924 shs	275,119 shs
HURA TuHURA Biosciences	$2.50 +2.0%	$3.54	$1.80 ▼ $7.93	$108.11M	0.23	231,365 shs	8,452 shs
MREO Mereo BioPharma Group	$2.87 +2.3%	$2.39	$1.58 ▼ $5.02	$452.36M	0.48	1.09 million shs	59,018 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	-0.89%	-1.33%	+34.55%	+59.71%	+65.67%
CMPS COMPASS Pathways	-3.45%	-5.88%	+12.56%	+46.41%	-34.12%
HURA TuHURA Biosciences	-4.67%	-9.93%	-37.50%	-36.36%	+244,999,900.00%
MREO Mereo BioPharma Group	+1.45%	+5.66%	+25.00%	+8.53%	-34.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	3.1162 of 5 stars	3.7	3.0	0.0	0.0	2.7	2.5	0.6
CMPS COMPASS Pathways	2.5065 of 5 stars	3.5	3.0	0.0	0.0	2.8	0.8	0.6
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	2.0241 of 5 stars	3.6	1.0	0.0	0.0	3.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.33	Buy	$8.67	251.59% Upside
CMPS COMPASS Pathways	3.00	Buy	$18.83	282.17% Upside
HURA TuHURA Biosciences	3.25	Buy	$12.67	406.67% Upside
MREO Mereo BioPharma Group	3.17	Buy	$7.67	167.60% Upside

Current Analyst Ratings Breakdown

Latest HURA, ATAI, MREO, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/16/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/3/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
3/28/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,593.03	N/A	N/A	$0.69 per share	3.57
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
MREO Mereo BioPharma Group	$10M	45.55	N/A	N/A	$0.39 per share	7.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	291.69%	122.09%	N/A
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)

Latest HURA, ATAI, MREO, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	HURA TuHURA Biosciences	-$0.13	-$0.15	-$0.02	-$0.15	N/A	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
CMPS COMPASS Pathways	0.15	8.91	8.91
HURA TuHURA Biosciences	N/A	1.54	1.54
MREO Mereo BioPharma Group	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
CMPS COMPASS Pathways	46.19%
HURA TuHURA Biosciences	0.62%
MREO Mereo BioPharma Group	62.83%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
CMPS COMPASS Pathways	3.93%
HURA TuHURA Biosciences	0.20%
MREO Mereo BioPharma Group	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
HURA TuHURA Biosciences	N/A	43.68 million	43.59 million	N/A
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable

HURA, ATAI, MREO, and CMPS Headlines

Recent News About These Companies

Brokers Offer Predictions for MREO FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Research Analysts Issue Forecasts for MREO FY2026 Earnings

June 11, 2025 | marketbeat.com

Mereo rebrands as Cedar Trace

June 10, 2025 | royalgazette.com

Investors Purchase Large Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO)

June 6, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Mereo BioPharma Group plc (NASDAQ:MREO)

June 5, 2025 | marketbeat.com

Mereo BioPharma Group plc (NASDAQ:MREO) Given Consensus Recommendation of "Buy" by Analysts

May 31, 2025 | marketbeat.com

Woodline Partners LP Buys Shares of 618,784 Mereo BioPharma Group plc (NASDAQ:MREO)

May 27, 2025 | marketbeat.com

Tema Etfs LLC Invests $3.12 Million in Mereo BioPharma Group plc (NASDAQ:MREO)

May 20, 2025 | marketbeat.com

Why Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.63%

May 16, 2025 | aaii.com

We're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Rate

May 15, 2025 | finance.yahoo.com

Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

May 13, 2025 | finanznachrichten.de

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

May 13, 2025 | globenewswire.com

Mereo acquires Dish Fiber

May 2, 2025 | advanced-television.com

Mereo BioPharma Group plc (MREO): A Bull Case Theory

April 18, 2025 | finance.yahoo.com

Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds?

April 16, 2025 | msn.com

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Mereo Biopharma Group Plc (MREO) and Doximity (DOCS)

April 9, 2025 | markets.businessinsider.com

Mereo BioPharma’s SWOT analysis: rare disease stock poised for breakthrough

April 2, 2025 | uk.investing.com

Mereo BioPharma initiated with an Overweight at JPMorgan

March 27, 2025 | markets.businessinsider.com

Cantor Fitzgerald Remains a Buy on Mereo Biopharma Group Plc (MREO)

March 27, 2025 | markets.businessinsider.com

JP Morgan Initiates Coverage of Mereo BioPharma Group plc - Depositary Receipt () (MREO) with Overweight Recommendation

March 27, 2025 | msn.com

Mereo BioPharma sees cash runway into 2027

March 27, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, ATAI, MREO, and CMPS Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.44 +0.23 (+10.14%)

As of 10:42 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

COMPASS Pathways NASDAQ:CMPS

$4.86 +0.38 (+8.57%)

As of 10:42 AM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

TuHURA Biosciences NASDAQ:HURA

$2.50 +0.05 (+2.04%)

As of 10:40 AM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Mereo BioPharma Group NASDAQ:MREO

$2.86 +0.05 (+1.96%)

As of 10:41 AM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time